ERBB2 and breast carcinoma: Various chemotherapeutic agents, have been reported to have higher risk of CTRCD [2], and patients with human epidermal growth factor receptor II (HER2)-positive breast cancer are particularly at high risk, since many of them receive anthracycline, anti-microtubule agents, and trastuzumab-based chemotherapy with or without radiation therapy, which are all known to have high risk of CTRCD.